Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03911453
Title Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Arizona

triple-receptor negative breast cancer



Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.